• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

www.nmpa.comJanuary 04, 2023

Tag: Ainuovirine , lamivudine

Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:复邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA. This product is a compound medicine composed of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate, which is indicated for the treatment of adult HIV-1 infected patients.

The marketing of this drug provides new treatment options for adult HIV-1 infected patients.

Previous:Mobocertinib succinate capsules approved for marketing with conditions

Next:China, New Zealand to further enhance science cooperation

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing - PharmaSources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Ibond® (Ainuovirine Tablets)

Ibond® (Ainuovirine Tablets)
Lamivudine

Lamivudine
4.4-Amino-1-(2r-hydroxymethyl-[1,3]oxathiolan-5s-yl)-1H-pyrimidin-2-one monosalicylate( lamivudine s

4.4-Amino-1-(2r-hydroxymethyl-[1,3]oxathiolan-5s-yl)-1H-pyrimidin-2-one monosalicylate( lamivudine s
Lamivudine

Lamivudine
99% up by HPLC Lamivudine 134678-17-4

99% up by HPLC Lamivudine 134678-17-4
Lamivudine

Lamivudine
Tenofovir Disoproxil Fumarate* Lamivudine

Tenofovir Disoproxil Fumarate* Lamivudine
Lamivudine*Zidovudine+Nevirapine

Lamivudine*Zidovudine+Nevirapine
Lamivudine Tablets (300mg, 150mg)

Lamivudine Tablets (300mg, 150mg)
Lamivudine api

Lamivudine api

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service